Consistent with the previous in vitro findings, EZH2/DMMT3B combo-inhibitor (GSK126 + 5-Aza) greatly inhibited tumor growth, showing a TGI rate of about 78.7% (Fig. 6E–G), but had no effect on mouse body weight (Supplementary Fig. S7A). Here, EZH2 is linked to neoplasm.